Evidence item

The small single-arm trial reported 95% objective response, 100% disease control, and 45% grade-three-or-higher treatment-related adverse events. DATASET_RESULT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 17687

Source: Tislelizumab plus lenvatinib in advanced fumarate hydratase-deficient renal cell carcinoma: a single-arm, phase 2 trial with metabolic biomarker analysis · locator {} · excerpt hash sha256:ecac69541a49890373982f7816d31434ea9e08889c8a081ade832a8c7edfe471

Exact excerpt

This phase 2 trial (NCT05877820) assessed first-line tislelizumab plus lenvatinib in advanced FH-RCC (N = 20). After a median follow-up of 20.2 months, ORR was 95% (95% CI 75.1–99.9), and DCR was 100% (95% CI 83.2–100). ... Grade ≥3 treatment-related adverse events occurred in 45% of patients. Limitations include the single-center, single-arm design, and limited sample size.

Linked claims

Claim	Direction	Relevance	Steps	Counted
adcd7b94	SUPPORT	DIRECT	0	yes

Audits

None.